Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
Open Access
- 1 August 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (8) , 1895-1900
Abstract
Objectives— Metabolic activity of cytochrome P450 (CYP) 3A4 has been associated with clopidogrel response variability. Because metabolic activity of CYP3A4 is genetically regulated, we hypothesized that genetic variations of this enzyme may contribute to clopidogrel response variability. Methods and Results— The CYP3A4*1B, CYP3A4*3, IVS7+258A>G, IVS7+894C>T, and IVS10+12G>A polymorphisms of the CYP3A4 gene were assessed in 82 patients in a steady phase of clopidogrel therapy. Glycoprotein (platelet glycoprotein (GP) IIb/IIIa receptor activation and platelet aggregation were assessed. A cohort of 45 clopidogrel-naïve patients was studied to determine the modulating effects of these polymorphisms after loading dose (300 mg) administration. Only the IVS7+258A>G, IVS7+894C>T, and IVS10+12G>A polymorphisms were sufficiently polymorphic. During the steady phase of clopidogrel treatment, IVS10+12A allele carriers had reduced GP IIb/IIIa activation ( P =0.025) and better responsiveness ( P =0.02); similarly, clopidogrel-naïve patients carriers of the IVS10+12A allele had reduced GP IIb/IIIa activation during the first 24 hours after a loading dose ( P =0.025), increased platelet inhibition ( P =0.006), and a more optimal drug response ( P =0.003). This polymorphism did not influence platelet aggregation profiles. No association was observed between the other polymorphisms and clopidogrel responsiveness. Conclusions— The IVS10+12G>A polymorphism of the CYP3A4 gene modulates platelet activation in patients treated with clopidogrel and may therefore contribute to clopidogrel response variability.Keywords
This publication has 30 references indexed in Scilit:
- Clopidogrel Effect on Platelet REactivity in Patients With Stent ThrombosisJACC, 2005
- Platelet Reactivity in Patients and Recurrent Events Post-StentingJACC, 2005
- Preclinical and Clinical Studies with Selective Reversible Direct P2Y12AntagonistsSeminars in Thrombosis and Hemostasis, 2005
- Variability in platelet responsiveness to clopidogrel among 544 individualsJACC, 2005
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel ResistanceCirculation, 2004
- Pharmacokinetics of clopidogrel after administration of a high loading doseThrombosis and Haemostasis, 2004
- The International HapMap ProjectNature, 2003
- Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With
P2Y
12
Gene Sequence Variations in Healthy SubjectsCirculation, 2003
- Clopidogrel for Coronary StentingCirculation, 2003